Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346 | Business Wire

Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346 | Business Wire: ANTIBE THERAPEUTICS RELEASES SECONDARY ENDPOINT DATA FROM RECENT PHASE 2B GASTROINTESTINAL SAFETY STUDY FOR LEAD DRUG, ATB-346